Zhejiang Huahai Pharmaceutical Co (SHSE:600521) Change In Receivables : ¥0 Mil (TTM As of Mar. 2024)

View and export this data going back to 2003. Start your Free Trial

What is Zhejiang Huahai Pharmaceutical Co Change In Receivables?

Zhejiang Huahai Pharmaceutical Co's change in receivables for the quarter that ended in Mar. 2024 was ¥0 Mil. It means Zhejiang Huahai Pharmaceutical Co's Accounts Receivable stayed the same from Dec. 2023 to Mar. 2024 .

Zhejiang Huahai Pharmaceutical Co's change in receivables for the fiscal year that ended in Dec. 2023 was ¥269 Mil. It means Zhejiang Huahai Pharmaceutical Co's Accounts Receivable declined by ¥269 Mil from Dec. 2022 to Dec. 2023 .

Zhejiang Huahai Pharmaceutical Co's Accounts Receivable for the quarter that ended in Mar. 2024 was ¥2,429 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Zhejiang Huahai Pharmaceutical Co's Days Sales Outstanding for the three months ended in Mar. 2024 was 88.69.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Zhejiang Huahai Pharmaceutical Co's liquidation value for the three months ended in Mar. 2024 was ¥-5,263 Mil.

Zhejiang Huahai Pharmaceutical Co Change In Receivables Historical Data

The historical data trend for Zhejiang Huahai Pharmaceutical Co's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhejiang Huahai Pharmaceutical Co Change In Receivables Chart

Zhejiang Huahai Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

497.18

-582.45

-388.87

-818.89

269.50

Zhejiang Huahai Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Zhejiang Huahai Pharmaceutical Co Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0 Mil.

Zhejiang Huahai Pharmaceutical Co (SHSE:600521) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Zhejiang Huahai Pharmaceutical Co's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	2428.525	/	2498.671	*	91
=	88.69

2. In Ben Graham's calculation of liquidation value, Zhejiang Huahai Pharmaceutical Co's accounts receivable are only considered to be worth 75% of book value:

Zhejiang Huahai Pharmaceutical Co's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	2896.706	-	11599.243	+	0.75 * 2428.525	+	0.5 * 3236.962
=	-5,263

Zhejiang Huahai Pharmaceutical Co Change In Receivables Related Terms

Thank you for viewing the detailed overview of Zhejiang Huahai Pharmaceutical Co's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Zhejiang Huahai Pharmaceutical Co (SHSE:600521) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zhejiang Huahai Pharmaceutical Co Ltd (SHSE:600521) » Definitions » Change In Receivables

Traded in Other Exchanges

N/A

Address

Economic Development Zone, Xunqiao Town, Linhai, Taizhou, Zhejiang, CHN, 317024

Website

http://www.huahaipharm.com

Zhejiang Huahai Pharmaceutical Co Ltd provides formulations, active pharmaceutical ingredients, and intermediates in China and internationally. The company also offers pril products, including captopril, enalapril, and lisinopril.

Executives

Chen Bao Hua	Director
Shang Fei	senior management
Du Jun	Director
Su Yan	Director
Chen Dun Yuan	senior management
Li Hong	Director
Guo Si Jia	senior management
Li Min	senior management
Xu Bo	senior management
Wang Jie	senior management
Chen Qi Mao	senior management
Zhang Hong	senior management
Zhang Mei	senior management
Zhu Yong Hua	Directors, senior managers
Wang Yi Hua	senior management

Zhejiang Huahai Pharmaceutical Co (SHSE:600521) Headlines

No Headlines